Background-Breast-feeding has important health and emotional benefits for both mother and infant, and should be encouraged. While there are some data to suggest migraine may improve during breast-feeding, more than half of women experience migraine recurrence with 1 month of delivery. Thus, a thorough knowledge base of the safety and recommended use of common acute and preventive migraine drugs during breast-feeding is vital to clinicians treating migraine sufferers. Choice of treatment should take into account the balance of benefit and risk of medication. For some of the medications commonly used during breast-feeding, there is not good evidence about benefits.
To some extent, most drugs transfer into breast milk. Exceptions include heparin and insulin as their size is too large to cross biological membranes. The transfer of drugs into breast milk is commonly described quantitatively using the milk to plasma (M/P) concentration ratio. The infant dose (mg/kg) can be expressed as a percentage of the maternal dose (mg/ kg). A cut-off of 10% has been recommended as a guide for the safe use of most drugs during lactation, with a very low risk of infant effects. 9, 10 Multiple factors influence the transfer of drugs into human breast milk and infant exposure to those drugs. Those lipophilic drugs with small molecular size, low maternal plasma protein binding, and weakly basic pH compared with milk are likely to have greater concentrations in breast milk. However, drugs that are hydrophilic, inhaled or topical, or have a high maternal first-pass metabolism are less likely to be in breast milk. Additionally, the age of the infant should be considered: premature infants clear drugs poorly, while by 7 months of age infants clear drugs at a rate similar to adults. 11 For drugs that appear in breast milk to any significant extent, it may be reasonable to reduce infant exposure by alternating breast and bottle-feeding, or by adjusting the timing of when the medication is taken relative to breast-feeding. This approach may be particularly useful for medications with a short half-life and acute migraine treatments.
While the potential effect of these medications on the nursing infant is the primary focus for the data collected, the primary objectives for this review article are as follows: (1) to summarize the current known data available for commonly used migraine medications used during lactation and (2) to provide a list of resources for clinicians to consult when making migraine treatment decisions in this population. It is hoped that this review article can be a valuable resource for headache clinicians treating lactating migraineurs.
METHODS
A literature search was performed to determine the most highly regarded sources of information about the use of migraine medication during breast-feeding. Four sources of information were identified, and were agreed upon by all the authors of this article to be the most useful and most reliable source of information. The rationale for selecting these sources will be discussed in the following section.
The first author contacted the AAP to determine if clinical guidelines for migraine medication use during lactation have been established. The AAP does not have established evidence-based guidelines on treating migraine in lactation. However, they have a "retired" policy statement called "The Transfer of Drugs and Other Chemicals Into Human Milk." 12 This policy statement does not designate drugs as "safe" or "unsafe"; rather, it lists drugs and other agents into tables based on what is known or has been reported about the effect of the drug on the infant or on lactation, if known. The 7 tables are as follows:
• A drawback of the AAP policy statement is that it was published in 2001 and has now been officially "retired" by the AAP. The designation of "retired" indicates that the 2001 publication no longer represents an official policy of the AAP. The AAP Committee on Drugs is preparing a new clinical report on selected therapeutics in lactation, with a projected completion in 2012. In the meantime, the AAP recommends the National Library of Medicine's Drugs and Lactation database (LactMed) as an excellent source of information concerning drugs to which breast-feeding mothers may be exposed. LactMed is a peerreviewed and fully referenced database that is part of the National Library of Medicine's TOXNET system. It can be accessed at http://toxnet.nlm.nih.gov. 13 The LactMed database includes information on drugs and lactation, including maternal levels of medications in breast milk, drug levels in infant blood, potential effects in breast-feeding infants, and effects on lactation. It is free and available for both providers and patients. A recent addition is a free downloadable application for handheld devices like iPhone. This database is updated every 1-2 months. LactMed does not assign any rating system to medication for lactation; it simply lists all that is known about a particular medication in regard to lactation.
A third resource is a comprehensive manual entitled Medications and Mothers Milk written by Thomas Hale, PhD. 14 In this manual, the author reviews scientific literature and assigns a lactation risk category (LRC) to all listed medications. This manual is updated more frequently than theAAP policy statement. It was last published in 2010 as the 14th edition. It is available as a paperback book and can be ordered online at http:// www.iBreastfeeding.com. This current edition is over 1000 pages. Medications are listed alphabetically using generic names. The index includes name brands to help locate the medication entry. Each drug monograph lists the pregnancy risk category as established by the Food and Drug Administration, Hale's LRC, and the AAP recommendations when available. Many medications have not been reviewed by the AAP committee. In this case, the monograph will state "not reviewed" for a particular drug. In addition, each listing shows the M/P ratio when it is known,potential drug interactions,and both adult and pediatric concerns. Hale's disclaimer in the manual's preface clarifies that he makes no recommendations as to the safety of these medications during lactation but only reviews what is currently published in the scientific literature. He emphasizes that individual use of medications must be left up to the judgment of the physician, the patient, and other healthcare consultants. Hale's LRCs are listed in Table 1 .
Another highly regarded and comprehensive reference examining the safety of medication in both pregnancy and lactation is Drugs in Pregnancy and Lactation by Briggs, Freeman, and Yaffe. 15 The authors provide recommendations for breast-feeding based in large part on human data, such as milk and maternal plasma levels, infant drug levels after exposure, and reported adverse events. Their categories for breast-feeding recommendations are listed in Table 2 .
For this paper, once the authors agreed upon the 4 reference sources, data for the use of migraine medication were collected and summarized. Commonly used migraine medications were divided into categories and listed by the generic names. In addition, the authors summarized the listings into tables for reference. Table 3 lists recommendations for commonly used acute migraine treatments, and Table 4 recommendations for commonly used migraine preventive drugs. In addition, each medication was researched by the first author of this review, utilizing LactMed for any additional up-to-date information. For details of the pharmacokinetics of each medication, including M/P ratio and maternal protein binding percentages, Hale's comprehensive manual and the Briggs/Freeman/Yaffe reference were used.
The AAP policy statement and the LRC as assigned by the Hale or the Briggs manual of a drug will often be different than what is found in the Physicians Desk Reference (PDR). This is because the PDR is a compendium of pharmaceutical manufacturers' package inserts. Most package inserts will designate drugs not to be used during breast-feeding due to lack of clinical studies done in breast-feeding mothers.
RESULTS

Acute Migraine Medications in Lactation
Simple Analgesics
1.
Acetaminophen: Compatible with breast-feeding by AAP. LRC L1. Briggs category: compatible.
2.
Aspirin: Associated with Reye's syndrome in infants. In infants of breast-feeding mothers taking aspirin, the potential adverse effects on platelet function is unclear. Peak milk levels occur at about 3 hours after ingestion and are eliminated more slowly from milk than plasma. 16 Should be given to nursing mothers with caution by AAP. LRC L3. Briggs category: potential toxicity. 
Non-Steroidal Anti-Inflammatory Drugs
2.
Ergotamine: Can decrease prolactin and decrease milk production. In one 1934 study, it was noted to cause vomiting, diarrhea, and convulsions in infants when doses used for migraine are taken by the nursing mother. 22 Use caution if given to nursing mothers by AAP. LRC L4. Briggs category: contraindicated.
Antiemetics and Neuroleptics
1.
Metoclopramide: Effect on infant is unknown by AAP. May increase breast milk production, although less potent than domperidone. 23 
5.
Chlorpromazine: Excreted in breast milk, and occasionally found in low concentrations in infant plasma and urine. Although no adverse events were noted with monotherapy, dual therapy with haloperidol was associated with decline in developmental scores between the 12 and 18 assessments. 24 Effect on nursing infants is unknown but may be of concern by the AAP. LRC L3. Briggs category: potential toxicity.
6.
Haloperidol: Found in breast milk at concentrations about one-half of maternal. No known adverse events noted. 25 Effect on nursing infants is unknown but may be of concern by the AAP. LRC L2. Briggs category: potential toxicity.
7.
Olanzapine: In 1 study, mean infant plasma levels were undetectable with no adverse effects on infants; 26 however, another study showed higher rates of breastfeeding discontinuation in subjects taking olanzapine compared with controls. 27 Not reviewed by the AAP. LRC L2. Briggs category: potential toxicity. 
2.
Codeine: Compatible with breast-feeding by the AAP. Four cases of neonatal apnea have been reported following administration of 60 mg codeine every 4-6 hours to breast-feeding mothers; apnea resolved after discontinuation of maternal codeine. 28 LRC L3. (Note: Although in the majority of women codeine is LRC L3, in rare conditions when a mother is a rapid metabolizer [a rare condition that leads to increased formation of morphine from codeine], codeine may be considered LRC L5; an infant death was reported in a case published in Lancet). 
Preventive Migraine Medications in Lactation
In this section, commonly used migraine preventive medications will be divided into categories and listed alphabetically. Hale's LRC, Briggs category, and the AAP rating will be listed. For medications not listed, clinicians are encouraged to use the resources listed in this article to get information about use during lactation.
Antidepressants: Tricyclic Antidepressants
1.
Amitriptyline: Drug concentrations of tricyclic antidepressants in breast milk are similar to plasma levels, 31 but these drugs and their metabolites do not appear to accumulate in infants. 32 Effect on nursing infants is unknown but may be of concern by the AAP. No pediatric adverse effects in several studies. LRC L2. Briggs category: potential toxicity.
2.
Nortriptyline: There are no detectable plasma drug levels in infants of mothers on chronic nortriptyline. 33 Effect on nursing infants is unknown but may be of concern by the AAP. No pediatric adverse effects in several studies. LRC L2. Briggs category: potential toxicity.
Doxepin:
Its long-lasting metabolite N-desmethyldoxepin may accumulate, and there is a case report of a near fatality in an 8-week-old infant. 34 Effect on nursing infants is unknown but may be of concern by the AAP. LRC L5. Briggs category: potential toxicity.
4.
Imipramine: There are relatively longer term studies in infants up to 2 years old with no detectable infant plasma levels and no adverse events. 35 Effect on nursing infants is unknown but may be of concern by the AAP. LRC L2. Briggs category: potential toxicity.
5.
Protriptyline: No known reports or effects, but its low molecular weight suggests that it would be excreted into breast milk. Not reviewed by the AAP and no LRC rating. Briggs category: potential toxicity.
Antidepressants: Others
1.
Bupropion: Effect on nursing infants is unknown but may be of concern by the AAP. One case of seizure in a 6-month-old. 36 LRC L3. Briggs category: potential toxicity.
2.
Citalopram: Not reviewed by the AAP. Two cases of excessive somnolence, decreased feeding, and weight loss have been reported. 37 However, the majority of studies show no or limited side effects in breast-fed infants. LRC L2. Briggs category: potential toxicity.
3.
Duloxetine: Not reviewed by the AAP. Milk levels in 1 study of 6 mothers were low, and no adverse pediatric effects have been reported. 38 LRC L3. Briggs category: potential toxicity.
Escitalopram: Not reviewed by the AAP. Reported data show relatively low infant dose in breast-fed infants and no adverse effects. LRC L2. Briggs category:
potential toxicity.
5.
Fluoxetine: Effect on nursing infants is unknown but may be of concern by the AAP. Severe colic, fussiness, and crying reported in 1 case study. 39 LRC L2. Briggs category: potential toxicity.
6.
Paroxetine: Effect on nursing infants is unknown but may be of concern by the AAP. A neonatal withdrawal effect may follow in utero exposure but no adverse effect noted in breast-fed infants. LRC L2. Briggs category: potential toxicity.
7.
Sertraline: Effect on nursing infants is unknown but may be of concern by the AAP. A published study of 11 mother/infant pairs suggests minimal transfer of sertraline into human milk. 40 
4.
Lamotrigine: Effect on nursing infants is unknown but may be of concern by the AAP. A study of 30 women on lamotrigine for seizure disorders reported infant plasma levels to be 18.3% of maternal plasma levels. 43 One case of severe apnea in a 16-day-old, breast-fed infant. 44 May produce significant plasma levels in some breast-fed infants, and monitoring of infant's plasma levels closely is recommended. LRC L3. Briggs category: potential toxicity. 
5.
3.
Atenolol: Associated with significant effects on some nursing infants and should be given to nursing mothers with caution by the AAP. One report of hypotension, bradycardia, and cyanosis in a breast-fed infant of a mother taking 100 mg daily. 46 LRC L3. Briggs category: potential toxicity.
4.
Candesartan: Not reviewed by the AAP. No pediatric concerns reported but caution is recommended as it may adversely affect the development of immature kidneys due to its action as an angiotensin receptor blocker on the renin-angiotensin system. LRC L3. Briggs category: probably compatible.
5.
Labetalol: Compatible with breast-feeding by the AAP. Only small amounts secreted into human milk in 1 study of 3 women receiving 600-1200 mg a day of labetalol. 47 No pediatric adverse events reported. LRC L2. Briggs category: probably compatible.
6.
Lisinopril: Not reviewed by the AAP. No breast-feeding data available on this product. Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, are contraindicated in the third trimester, but other ACE inhibitors, such as captopril or enalapril, may be used in term infants several weeks post-partum. 48 LRC L3. Briggs category: probably compatible.
7.
Metoprolol: Compatible with breast-feeding by the AAP. No pediatric concerns have been reported. However, observation for hypotension, weakness, and bradycardia is advised. LRC L3. Briggs category: potential toxicity. 
Miscellaneous
1.
Onabotulinumtoxin A: Not reviewed by the AAP. Botulinum is not secreted into breast milk as long as it is injected properly into the muscle. LRC L3. Briggs category: probably compatible.
2.
Alprazolam: Effect in infants is unknown but may be of concern by the AAP. A neonatal withdrawal syndrome was evident in a breast-fed infant first week postpartum; the mother took 0.5 mg 2-3 times daily during pregnancy and postpartum. 49 This data suggest that the amount of alprazolam in breast milk was insufficient to prevent a withdrawal syndrome. LRC L3. Briggs category: potential toxicity.
3.
Clonazepam: Not reviewed by the AAP. In a group of women receiving 2 mg or less per day, with or without quetiapine or paroxetine, no drug was detected in breast milk. 50 Low incidence of toxicity is suggested by available data. LRC L3. Briggs category: potential toxicity. 
10.
Quetiapine: One study of quetiapine in breast milk suggested that the levels are too low to affect infants. 51 Not reviewed by the AAP LRC L2. Briggs category: potential toxicity.
11.
Cyproheptadine: Not reviewed by the AAP. Can lower prolactin levels with chronic use and affect lactation. 52 Contraindicated by manufacturer because of increased sensitivity of newborns to antihistamines. 30 LRC L3. Briggs category: probably compatible.
There is little known information about the safety of many nutraceutical products in breastfeeding.This includes preventive treatments for migraine, such as coenzyme Q10 and petasites (butterbur), although coenzyme Q10 is present in breast milk normally. 53 
DISCUSSION
There are no evidence-based guidelines for the treatment of migraine during breast-feeding. Current data and recommendations are limited by the lack of clinical studies done in breastfeeding women and the very small numbers reported in case reports or small published studies. However, despite these limitations, there are many treatment options for migraine that are compatible with breast-feeding. Excellent resources are available to help clinicians in making treatment decisions in the breast-feeding female migraine patient. Suggested resources include the following: An open discussion with our patients about available resources, and the risks and benefits of various medications while nursing, can foster a collaborative approach to migraine treatment during breast-feeding. Consideration of potential efficacy should be taken into account when making treatment decisions. Updated guidelines for the prevention of episodic migraine were completed in 2012 by the American Headache Society and the American Academy of Neurology. 54 Awareness of these guidelines, including the level of evidence for a particular medication being considered, should be considered when making treatment decisions in breast-feeding women. For acute migraine treatment, the United States Headache Consortium Guidelines can be helpful in balancing safety with efficacy of a particular treatment. 55 The best approach is often to see the patient in the third trimester before giving birth to discuss if the mother will breast-feed after giving birth, and the potential risks of acute and preventive migraine medication. For acute migraine, medications with very low absorption into breast milk may be appropriate, with no need to discontinue breast-feeding. As examples, ibuprofen and eletriptan have very low levels in breast milk, and many acute medications have short half-lives, making it fairly easy to briefly discontinue breast-feeding. The decision to use preventive medication while breast-feeding is more complicated. For women with a history of refractory migraine, long-lasting or especially disabling migraine, or history of migraine worsening soon after a previous pregnancy, it may be reasonable to start preventive medication immediately after giving birth and bottle feeding, or to only use preventive medication with very low concentrations in breast milk. For women previously treated successfully with a particular preventive, it may be worth restarting that same medication soon after delivery. For women with episodic migraine for whom acute medications are effective and in those doing well during pregnancy, it may be reasonable to delay preventive medication to allow women to breast-feed. Breast-feeding while taking medications may be higher risk to preterm infants in their first month or two as their ability to metabolize drugs is lower.
A follow-up visit after giving birth should address migraine frequency and severity if the mother is breast-feeding, and if so how long she plans to do so. The majority of women breast-feed in the early post-partum period, but less than half of women continue to breastfeed at 6 months and only about 30% of women exclusively breast-feed at 3 months. 56 A few medications that are considered high risk in pregnancy may be relatively safer for breast-feeding due to low concentrations in breast milk, such as valproate. Starting at lower doses and titrating up more slowly than usual is 1 strategy. For example, when starting topiramate, this might mean starting at 15 mg instead of 25 mg, or increasing the dose every 2-3 weeks instead of weekly. For tricyclic antidepressants, such as amitriptyline or nortriptyline, this may mean starting at 10 mg rather than 25 mg. Starting at low doses allows the ability to assess for any adverse effects on the infant, such as sedation, and within the first months of life infant metabolism rapidly increases.
In the absence of controlled clinical trials and evidence-based guidelines, health care providers can strive to make good treatment decisions based on the pharmacological data that are currently available. Our migraine patients desirous of breast-feeding will benefit from our awareness of what is known about medication use during breast-feeding. Table 1 Hale's Lactation Risk Categories L1 SAFEST: Drugs have been taken by a large number of breast-feeding women without any observed increase in adverse effects in the infant. Controlled studies in breast-feeding women fail to demonstrate risk to the infant, and the possibility of harm to the breast-feeding infant is remote, or the product is not orally bioavailable in an infant.
L2 SAFER:
Drugs that have been studied in a limited number of breast-feeding women without an increase in adverse effects in the infant. And/or the evidence of a demonstrated risk that is likely to follow use of this medication in a breast-feeding woman is remote.
L3 MODERATELY SAFE:
Drugs for which there are no controlled studies in breast-feeding women; however, the risk of untoward effects to a breast-fed infant is possible, or controlled studies show only minimal nonthreatening adverse effects. Drugs should only be given if the potential benefit justifies the potential risk to the infant. (New medications that have no published data are automatically put into this category, regardless of how safe they may be.)
L4 POSSIBLY HAZARDOUS:
Positive evidence of risk to a breast-fed infant or to breast milk production, but the benefits from use in breastfeeding mothers may be acceptable despite the risk to the infant (eg, if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
L5 CONTRAINDICATED: Significant and documented risk to the infant. Drug should not be used as the risk outweighs any possible benefit.
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